Next Article in Journal
The Potential Use of Honey as a Neuroprotective Agent for the Management of Neurodegenerative Diseases
Next Article in Special Issue
Association between Hypertension and Stroke Recurrence as Modified by Pro-oxidant–Antioxidant Balance: A Multi-Center Study
Previous Article in Journal
Inferior Nutritional Status Significantly Differentiates Dialysis Patients with Type 1 and Type 2 Diabetes
Previous Article in Special Issue
Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 15
Issue 7
10.3390/nu15071557
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Combined Citrulline and Glutathione Supplementation Improves Endothelial Function and Blood Pressure Reactivity in Postmenopausal Women

by
Arturo Figueroa
1,*,
Arun Maharaj
1,2,
Yejin Kang
1,
Katherine N. Dillon
1,
Mauricio A. Martinez
1,
Masahiko Morita
3,
Dai Nogimura
3 and
Stephen M. Fischer
1
1
Department of Kinesiology and Sport Management, Texas Tech University, Lubbock, TX 79409, USA
2
Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
3
Research & Development Division, KIRIN Central Research Institute, Kirin Holdings Co., Ltd., 2-26-1, Muraoka-Higashi, Fujisawa 251-8555, Kanagawa, Japan
*
Author to whom correspondence should be addressed.
Nutrients 2023, 15(7), 1557; https://doi.org/10.3390/nu15071557
Submission received: 16 February 2023 / Revised: 7 March 2023 / Accepted: 21 March 2023 / Published: 23 March 2023
(This article belongs to the Special Issue Cardiometabolic Health in Relation to Diet and Physical Activity: Experimental and Clinical Evidence)
Browse Figures
Versions Notes

Abstract

:
Postmenopausal women (PMW) may experience endothelial dysfunction associated with arginine (ARG) deficiency relative to asymmetric dimethylarginine (ADMA) caused by oxidative stress. Endothelial dysfunction contributes to increased blood pressure (BP) responsiveness to sympathoexcitation induced by the cold pressor test (CPT). We investigated the effects of citrulline alone (CIT) and combined with the antioxidant glutathione (CIT+GSH) on vascular function. Forty-four healthy PMW were randomized to CIT (6 g), CIT+GSH (2 g + 200 mg: Setria®) or placebo (PL) for 4 weeks. Brachial artery flow-mediated dilation (FMD), aortic stiffness (pulse wave velocity, PWV), brachial and aortic BP reactivity to CPT, and serum fasting blood glucose (FBG), ARG, and ARG/ADMA ratio were measured. Baseline FBG was higher in CIT+GSH vs. PL. FMD increased after CIT+GSH vs. PL (p < 0.05). CIT and CIT+GSH increased ARG/ADMA (p < 0.05), but did not affect aortic PWV. CIT+GSH attenuated the brachial and aortic systolic BP and mean arterial pressure (MAP) responses to CPT vs. PL and CIT (p < 0.05). The improvements in FMD were related to baseline FMD (r = −0.39, p < 0.05) and aortic MAP response to CPT (r = −0.33, p < 0.05). This study showed that CIT+GSH improved FMD and attenuated systolic BP and MAP reactivity in PMW. Although CIT increased ARG/ADMA, it did not improve FMD in healthy PMW.

1. Introduction

The endothelium has a major role in the regulation of vascular function and structure by releasing vasodilatory molecules [1]. Nitric oxide (NO), the main vasodilator, is produced from the amino acid L-arginine (ARG) by endothelial NO synthase (eNOS) [2] in response to increased shear stress induced by blood flow. NO is the primary endothelial factor for relaxing vascular smooth muscle cells and preventing pathological structure remodeling that leads to arterial stiffness [1,3]. Reduced NO availability, a main cause of endothelial dysfunction [1,3], is associated with ARG deficiency driven by increased levels of endogenous inhibitors of eNOS [4] and ARG catabolism to ornithine (ORN) by the enzyme arginase [5,6]. Oxidative stress is a main mechanism of endothelial dysfunction via increasing asymmetric dimethylarginine (ADMA, an eNOS inhibitor) levels [7,8,9] and arginase activity [10]. Since ARG and ADMA compete for binding to eNOS, a low ARG/ADMA ratio is a biomarker of reduced ARG availability and NO production [7].
Impaired endothelial function, assessed as low brachial artery flow-mediated dilation (FMD), begins before and progresses after menopause in healthy women [4,11]. Endothelial dysfunction precedes the development of arterial stiffness [12] and hypertension in healthy postmenopausal women [13]. Another mechanism for hypertension in postmenopausal women is elevated sympathetic activity [14]. Systolic hypertension and consequent heart failure with preserved ejection fraction are highly prevalent in older women due to increased aortic stiffness [15] and sympathetic-mediated vasoconstriction [16,17]. Evidence indicates that augmented systolic blood pressure (BP) reactivity to a sympathetic stimulus (cold pressor test, CPT) predicts future hypertension [18] and heart failure [19]. Exaggerated BP reactivity to sympathetic stimuli seen in postmenopausal women [16], may be due to the inability of the endothelium to counteract sympathetic-mediated vasoconstriction [17,20].
Dietary strategies to increase circulating ARG may improve vascular function. The effectiveness of short-term oral ARG supplementation for improving FMD was observed in healthy older adults [21]. However, oral ARG becomes ineffective for vascular benefits due to stimulation of arginase activity [22]. Contrary to ARG, citrulline (CIT) is not catabolized by arginase and inhibits arginase activity [23], and thus, is more efficient than oral ARG in increasing circulating ARG levels [24]. Short-term CIT supplementation has been shown to improve plasma ARG, ARG/ADMA, arterial stiffness, and resting BP in middle-aged and older adults [23,25,26,27,28,29]. Evidence supports the benefit of CIT supplementation on the attenuation of BP reactivity to CPT in healthy adults [30,31,32]. A placebo-controlled study examined the effect of CIT supplementation on FMD but failed to detect improvements in healthy adults [24]. Since oxidative stress is implicated in endothelial dysfunction, the addition of the antioxidant glutathione (GSH) may synergize the vascular benefits of CIT. Recent evidence supports the combined use of CIT and GSH (CIT+GSH) to improve eNOS activity in a mouse ischemia model [33] and the long-lasting increase of plasma NO levels in young men [34]. Although combined CIT+GSH supplementation increased post-exercise plasma NO metabolites (NOx), an indicator of improved endothelial function [34], vascular function measures were not evaluated. Therefore, it is unknown whether CIT+GSH supplementation can improve vascular function and BP reactivity in postmenopausal women. Given that CIT supplementation increased circulating ARG levels and the ARG/ADMA ratio, an indicator of increased NO availability [27], improvements in brachial FMD are expected in postmenopausal women.
The purpose of this study was to investigate the effects of supplementing with CIT alone and CIT+GSH on vascular function, assessed by brachial FMD, arterial stiffness (pulse wave velocity, PWV), and BP reactivity to CPT in postmenopausal women. Moreover, we assessed fasting blood glucose (FBG), serum levels of ARG and its metabolites, and markers of oxidative stress. Our hypothesis was that CIT alone and CIT+GSH supplementations would increase brachial FMD and attenuate BP responses to sympathetic activation induced by CPT compared to a placebo in postmenopausal women.

2. Materials and Methods

2.1. Participants

Participants were healthy postmenopausal women aged 51–74 years. All participants had absence of menstruation for at least 1 year and were sedentary (<120 min/week of exercise). Potential participants were excluded if they had diagnosed cardiovascular diseases (CVDs), type 2 diabetes, a body mass index > 34.9 kg/m2, brachial BP > 150/90 mmHg, consumed > 7 alcoholic drinks per week, and used tobacco, hormone replacement therapy, or dietary supplements with vasodilatory and/or antioxidant effects. The rationale for excluding women with a BP > 150/90 mmHg and > 7 alcoholic drinks was the increased CVD risk associated with these levels [35,36]. The study was registered in ClinicalTrials.gov (Identifier: NCT04672447) and the protocol was approved by the Texas Tech University Institutional Review Board.

2.2. Experimental Protocol

This was a double-blind, placebo-controlled, parallel design study. The randomization was performed by a researcher not involved in laboratory measurements using a block scheme stratified by age and systolic BP (SBP) with a computer program [37]. Forty-four participants were randomly assigned to a daily supplementation with a placebo (crystalline cellulose) (n = 17), CIT (6 g) (n = 13) or CIT+GSH (2 g + 200 mg: Setria®) (n = 14) (Figure 1). Participants consumed 9 capsules in the morning and evening for 4 weeks (Kyowa Hakko Bio Co., Ltd., Tokyo, Japan). Each capsule containing CIT, CIT+GSH, and placebo was indistinguishable by size, shape, and taste. Both research staff and participants were blinded to the group allocation until the completion of data analysis. Participants were instructed to avoid ARG or CIT rich containing foods (e.g., watermelon, salmon, nuts [walnuts, almonds], turkey breast) or supplements with NO precursors or antioxidants during the study period. Participants were recommended to maintain their usual diet and physical activity throughout the study. The last capsules were consumed 10–12 h before their laboratory visit at the end of the study. Participants returned their bottles during the last visit and adherence was assessed by capsule count.
The primary endpoint was the change in endothelial function, as assessed by brachial FMD. The secondary endpoints were reductions in PWV at rest and BP responses to CPT. Tertiary endpoints were changes in serum glucose, insulin, ARG, CIT, ORN, ADMA, arginase I, and oxidative markers.
Participants completed a health-history questionnaire and were familiarized with the protocol. Height and weight were measured using a stadiometer and beam scale (free-standing portable height rod and weigh beam, Detecto, Webb City, MO, USA), and waist circumference was measured using a non-elastic tape. Body mass index was calculated as weight (kg) divided by height squared (m2) and body composition was assessed using a total body dual-energy X-ray absorptiometry scanner (GE Lunar Prodigy; GE Healthcare, Madison, WI, USA).

2.3. Measurements

All measurements were performed in the morning after an overnight fast and 24 h abstinence from caffeine, alcohol, prescription medications, and physical activity. All vascular measurements were conducted in the supine position after at least 20 min of rest in a quiet, dimly lit, and thermoneutral environment. Following 4 weeks of intervention, all measurements were repeated in the same order and conducted at baseline.

2.3.1. Flow-Mediated Dilation

Endothelial function was assessed by brachial FMD. The right brachial artery was scanned ~2–3 cm proximal to the antecubital fossa using a 12-MHz linear array Doppler ultrasound probe (LogiQ S7 expert, GE Medical Systems, Milwaukee, WI, USA) at an insonation angle < 60°. Following a 2 min baseline diameter and mean blood velocity recording, the occlusion cuff on the proximal forearm was rapidly inflated to 250 mmHg using an automated pump (E20, Hokanson, Bellevue, WA, USA). Following a 5 min occlusion period, the cuff was rapidly deflated while the diameter and mean blood velocity were continuously recorded for 3 min using open-source software (OBS Studio). Baseline and peak diameters were measured using an automated edge-detection software (Quipu Cardiovascular Suite, Pisa, Italy). Baseline diameter was measured as the average vessel diameter during the 2 min baseline, and peak diameter as the largest diameter detected post-occlusion. FMD is expressed as a percentage change from the baseline diameter: FMD% = ([peak diameter − baseline diameter]/baseline diameter) × 100.

2.3.2. Pulse Wave Velocity

Carotid-femoral PWV (cfPWV, aortic), carotid-radial PWV (crPWV, brachial), carotid-distal PWV (cdPWV, systemic), and femoral-ankle (dorsalis pedis artery) PWV (faPWV, leg) were determined by applanation tonometry (Complior Analyse, Alam Medical, Vincennes, France; for faPWV: SphygmoCor CPV, AtCor Medical, Sydney, Australia). Distances between arterial sites in each segment were measured with a segmometer (Mitutoyo, Aurora, IL, USA). PWV was calculated as the distance of the arterial segment divided by the transit time of the pulse. cfPWV was multiplied by 0.80 to account for the distance between the carotid artery site and the suprasternal notch [38]. A minimum of two PWV measurements were obtained and the average was used for analysis.

2.3.3. Brachial and Aortic Blood Pressures at Rest and During the CPT

Brachial SBP and diastolic BP (DBP) were measured using an automated oscillometric device (HEM-705CP; Omron Healthcare, Vernon Hill, IL, USA). Radial artery pressure waves recorded using applanation tonometry were calibrated with brachial mean arterial pressure (MAP) and DBP. Aortic hemodynamics were obtained via a validated transfer function (SphygmoCor CPV; AtCor Medical, Sydney, Australia). A minimum of two high-quality readings (operator index ≥ 80%) were obtained at rest and during the CPT and the average was used for analysis. The participants introduced their right hand up to the wrist in cold water at 1–4 °C for 2 min. The increase in BP from rest to the second minute of the CPT (Δ) was used for the analysis, since greater sympathetic activity occurs at this time point [16].

2.3.4. Serum Biomarkers

Fasted blood samples were collected from the antecubital vein at baseline and at 4 weeks. Serum samples were collected using silicone-coated tubes and stored at −80 °C until subsequent analysis of the biomarkers. Glucose (EIAGLUC; Invitrogen, Carlsbad, CA, USA) was measured using the glucose oxidase method. Insulin was measured using an ELISA kit (80-INSHUE01.1, ALPCO Diagnostics, Salem, NH, USA). The homeostatic model assessment for insulin resistance was calculated as [fasting glucose (mg/dL) × fasting insulin (μIU/mL)]/405. Glutathione peroxidase (ab102530; Cambridge, UK), malondialdehyde (Abcam 233571; Cambridge, UK), and superoxide dismutase (ab119520; Cambridge, UK) were analyzed using the colorimetric method. Arginase-1 (BMS2216; Invitrogen, Carlsbad, CA, USA) and oxidized low-density lipoprotein (CSB-E07931h; Cusabio Biotech, Houston, TX, USA) were measured using ELISA kits. Serum ARG, CIT, ORN, and ADMA were analyzed using an AbsoluteIDQ p400 HR kit (Biocrates, Innsbruck, Austria), which is a combined flow injection and high-performance liquid chromatography–tandem mass spectrometry assay. The tandem mass spectrometry platform consisted of a Thermo Scientific Vanquish HPLC coupled to the Thermo Scientific Q-Exactive HF Quadrupole-Obitrap mass spectrometer.

2.4. Statistical Analysis

Sample size was estimated based on data that showed increased FMD after ARG supplementation in older adults [21]. It was estimated that 12 participants would be appropriate to detect a difference with ≥80% power at the α = 0.05 level. The Shapiro–Wilk test was used to verify the normal distribution of the data. A one-way analysis of variance was used to detect between-group differences. A two-way analysis of variance with repeated measures and Bonferroni adjustments were performed to detect time (before and after) and between-groups (placebo, CIT and CIT+GSH) differences in measures at rest and BP responses (Δ) to CPT. If significant time-by-group interactions were detected, Tukey and paired-t tests were used as post-hoc tests. Pearson’s correlation coefficient was used to evaluate relationships between changes in FMD% from 0 to 4 weeks and baseline FMD, and with aortic MAP responses to CPT from 0 to 4 weeks. Independent sample t-tests were used to evaluate low (0.20), moderate (0.50), and large (≥0.80) effect sizes using Cohen’s d on the changes in FMD between CIT vs. placebo, CIT+GSH vs. CIT, and CIT+GSH vs. placebo. Statistical analyses were performed using SPSS Ver26 (IBM SPSS, Armonk, NY, USA). Results are reported as the mean ± standard deviation (SD) in tables and the mean ± standard error (SE) in figures. Significance was set a priori at p < 0.05.

3. Results

3.1. Participant Characteristics

Participants were recruited from June 2020 to December 2021. Thirty-nine participants randomized to the placebo (n = 13), CIT (n = 13), and CIT+GSH (n = 13) completed the study (Figure 1). Compliance to the supplements were 94.9 ± 1.3%, 95.7 ± 1.1%, and 95.5 ± 1.2% for placebo, CIT, and CIT+GSH groups, respectively. No adverse effects of the supplementations were reported by participants during the study.
Participant characteristics at baseline did not differ among the groups, except for FBG (Table 1). FBG was higher in CIT+GSH compared to the placebo but not to CIT (p = 0.29).

3.2. Flow-Mediated Dilation and Arterial Stiffness

Baseline FMD and PWV segments did not differ among the groups. There was a time-by-group interaction for FMD. CIT+GSH increased the FMD by 2.9% (p = 0.045) compared with placebo, but not with CIT (p = 0.18) (Figure 2). A low effect size was seen between CIT and placebo (d = 0.32) and, although insignificant (p = 0.10), there was a moderate effect size between CIT+GSH and CIT (d = 0.67). To compliment the significant increase in FMD, there was a high effect size between CIT+GSH and placebo (d = 0.91, p = 0.03). The change in FMD from 0–4 weeks was correlated with the baseline FMD (Figure 3). The Pearson correlation coefficient for placebo, CIT, and CIT+GSH were −0.26 (p = 0.39), 0.16 (p = 0.60), and −0.68 (p = 0.01), respectively. There were no significant time-by-group interactions for cfPWV, crPWV, cdPWV, or faPWV. However, CIT+GSH supplementation decreased crPWV (arm PWV) by 0.66 ± 0.93 m/s (p = 0.05, Table 2).

3.3. Blood Pressure at Rest and During the Cold Pressor Test

Table 3 shows the BP at rest and during the CPT before and after the supplementations. There were no significant between-group differences in the resting BP at baseline and no time-by-group interactions. There were significant time-by-group interactions for changes (Δ) in brachial SBP (p = 0.02), brachial MAP (p = 0.04), aortic SBP (p = 0.03), and aortic MAP (p = 0.04) responses to the CPT. CIT+GSH supplementation reduced ΔSBP compared to the placebo and CIT (p < 0.05 for both), and reduced ΔMAP compared to the placebo (p < 0.05) but not to CIT (Figure 4). No significant time-by-group interactions were observed for ΔDBP, Δ augmentation index normalized to a heart rate of 75, and Δ reflection time (Tr). Attenuation of aortic ΔMAP was significantly related to the improvement in FMD% (r = −0.33, p < 0.05).

3.4. Serum Biomarkers

Table 4 shows serum biomarkers before and after the interventions. Significant time-by-group interactions were observed for ARG (p = 0.005), ORN (p = 0.04), and ARG/ADMA ratio (p = 0.007). ARG and ARG/ADMA ratios were significantly increased by CIT supplementation compared with placebo (p = 0.01 for both) and CIT+GSH (p = 0.008 and p = 0.04, respectively) (Figure 5A,D). The ARG/ADMA ratio significantly increased after CIT+GSH (p = 0.04). ORN was increased after CIT compared to CIT+GSH (p = 0.05) but not to the placebo (p = 0.12). Arginase I levels decreased after CIT (p = 0.01) and tended (p = 0.07) to decrease after CIT+GSH, but there was no significant time-by-group interaction. Glucose, insulin, homeostatic model assessment for insulin resistance, glutathione peroxidase, superoxide dismutase, oxidized LDL, and malondialdehyde did not significantly change after 4 weeks in any group.

4. Discussion

This study examined the effects of 4 weeks of CIT and CIT+GSH supplementation on vascular function and BP responsiveness in healthy postmenopausal women. We found that CIT+GSH supplementation improved endothelial function through an increase in the ARG/ADMA ratio. Although CIT supplementation increased serum ARG levels and the ARG/ADMA ratio, it did not statistically improve FMD. In addition, CIT+GSH supplementation attenuated BP responsiveness to CPT. These data show that CIT+GSH supplementation has protective cardiovascular effects at rest and during sympathetic stimulation (CPT) in healthy postmenopausal women.
FMD decreases progressively throughout the stages of the menopausal transition in healthy women [4]. Low FMD is a valuable biomarker for predicting future cardiovascular events in apparently healthy adults [39]. In this study, we showed that 4 weeks of CIT+GSH supplementation increased brachial FMD by 2.9% in healthy postmenopausal women. Consistent with our findings, a non-placebo controlled study observed a beneficial effect of CIT supplementation for 4 weeks on FMD in middle-aged patients with vasospastic angina and low FMD [40]. Similarly, 2 weeks of ARG supplementation increased FMD by 3.1% in healthy older men with age-related endothelial dysfunction [21]. A previous meta-analysis suggested that ARG supplementation improves FMD in individuals with baseline FMD values < 7.0% [41]. These previous findings suggest that CIT and ARG improve FMD in individuals with low FMD. Our data suggest that improvements in FMD following CIT+GSH mainly occurred in women with a low baseline FMD. Importantly, we found that the increase in FMD after 4 weeks of CIT+GSH was 0.91 SD greater vs. placebo and 0.67 SD greater vs. CIT alone. Given that for each 1 SD increase in FMD there is an associated 50% lower risk of cardiovascular events [42], our findings are clinically important.
Recent data showed that FMD values lower than 5.4% are indicative of impaired endothelial function in apparently healthy adults [43]. Based on this FMD reference value, 85% of women in the CIT+GSH group had low FMD, and thus, had impaired endothelial function at baseline. Evidence indicates that cardiometabolic risk factors, including BP and FBG, are determinants of low FMD [43]. Independent of traditional cardiovascular risk factors, low FMD predicts CVD risk [44]. In our study, an elevated baseline FBG was observed in the CIT+GSH group. Based on FBG values in the CIT+GSH group, four and seven participants had prediabetes or an increased risk of incident prediabetes, respectively [45]. It is known that prediabetes can negatively impact the age-related decline in FMD [46,47]. We demonstrate that CIT+GSH supplementation increased the mean FMD above 5.4% in a group of postmenopausal women with elevated FBG. Considering that a 4.3% increase in FMD is associated with 50% CVD risk reduction [42], the 2.8% improvement in FMD following 4 weeks of CIT+GSH may reduce the risk of cardiovascular events in apparently healthy postmenopausal women.
Age associated arterial stiffening affects the aorta to a greater extent than peripheral muscular arteries [48]. In older women, 10 years of aging have a greater impact on aortic PWV (+2.4 m/s) than brachial PWV (+0.19 m/s), indicating that peripheral arteries have less stiffening than the aorta [48]. A widely used measure of arterial stiffness is brachial-ankle PWV (baPWV), a segment that includes central (aortic PWV) and peripheral (brachial and leg PWV) arteries [49]. Since peripheral arteries have relatively more smooth muscle cells than collagen fibers [48], brachial PWV and leg PWV are more responsive to NO-mediated vasodilation than the aorta [50,51]. Oral CIT supplementation (5.6 g daily) for 1 week significantly reduced baPWV by ~0.14 m/s in middle-aged men with high baseline baPWV [27]. A further study clarified that the beneficial effect of CIT (6 g daily) on baPWV was due to a reduction of leg PWV (~0.40 m/s) with no effect on aortic PWV in obese postmenopausal women [29]. In the present study, aortic PWV was not reduced by CIT and CIT+GSH supplementations. This ineffectiveness may be attributed to the normal baseline values of our participants, which are considered to be ~7.6 m/s for adults aged ≥50 years [38]. Importantly, CIT+GSH decreased brachial PWV by ~0.40 m/s in postmenopausal women with increased risk of prediabetes. This finding is in agreement with previous studies [27,29] and confirms that peripheral arteries are more responsive than the aorta to dietary supplementation with NO precursors. The decrease in brachial PWV observed in the current study may be attributed to enhanced endothelial-mediated vasodilation [51].
Impaired FMD and increased sympathetic activity are associated with the increased risk of incident hypertension in healthy postmenopausal women [13,14]. Our participants had a normal or elevated SBP at rest. Our observation that the resting BP was unaffected by CIT and CIT+GSH supplementations is consistent with previous studies in normotensive adults [30,32] and middle-aged adults with elevated SBP and FBG [27]. Thus, we used the CPT as a systemic sympathetic vasoconstrictor stimulus to evaluate the efficacy of dietary supplements for attenuating BP reactivity to CPT [18,19]. We observed reductions of brachial and aortic SBP and MAP responses to CPT after CIT+GSH but not CIT supplementation. Previous evidence of blunted BP responsiveness to CPT after 2 weeks of CIT (6 g/day) was observed in healthy young [31] and older adults [32]. However, we did not measure FMD in those previous studies. In mice, CIT supplementation attenuated cold hypersensitivity by improving endothelial function [52]. In the current study, the attenuation of aortic MAP reactivity to CPT was related to improvements in FMD. This finding suggests that improved FMD with CIT+GSH supplementation may reduce the risk of cardiovascular events related to the augmented aortic BP load during conditions with increased sympathetic stimulation [16,19,53].
ADMA competes with ARG for binding to eNOS, thereby a decrease in ARG/ADMA leads to reduced NO production [54]. Evidence supports that the ARG/ADMA ratio is a better biomarker of endothelial function than circulating ARG and ADMA levels alone [7,55]. Our participants had normal ARG/ADMA values at baseline [56]. However, the CIT+GSH group tended to have a lower ARG/ADMA ratio, which has been associated with hyperglycemia [57]. In the present study, CIT and CIT+GSH supplementations increased the ARG/ADMA ratio, suggesting increased ARG availability for NO production [54]. This finding is consistent with Ochiai et al. [27] who reported an increase in plasma ARG/ADMA due to the isolated increase in ARG levels. CIT supplementation increases circulating ARG via de novo synthesis in the kidneys [54]. Serum ARG introduction to endothelial cells via the cationic amino acid y+ transporter 1 depends on both ARG and ADMA levels, since they compete for the transporter [58]. Therefore, a greater ARG availability displaces ADMA from eNOS binding, thereby improving NO synthesis [7,27,40,54,59]. A recent study reported that 2 g of CIT for 4 weeks increased NOx levels in type 2 diabetes patients as a result of arginase inhibition [23]. These findings suggest that a low dose of CIT may improve endothelial function in individuals with hyperglycemia. In the study by Ochiai et al., the increase in ARG/ADMA was evident after CIT supplementation in men with FBG in the prediabetes category [27]. Therefore, augmented ARG/ADMA ratio may explain the improvement in endothelial function following CIT and ARG supplementations in adults with hyperglycemia [27] and low baseline FMD [21,40,60].
Despite greater increases in the serum ARG levels and ARG/ADMA ratio, FMD did not improve after CIT supplementation alone. This discrepancy in the findings may be explained by the healthy status of the participants. In agreement with our findings, ARG supplementation for 4 weeks increased serum ARG levels by almost double but failed to improve FMD in healthy postmenopausal women [61]. Similarly, 6 g of CIT supplementation efficiently increased circulating ARG levels and ARG/ADMA without affecting FMD in healthy adults [24]. In the present study, the increase in ARG levels positively increased the ARG/ADMA ratio, indicating improved ARG availability for NO production. Similarly, previous studies failed to show improvement in endothelial function assessed as increased NOx after oral ARG and CIT supplementations in healthy adults [25,62]. Thus, increased ARG availability via CIT or ARG supplementation may not improve endothelial function in individuals with normal FMD [24,61]. Of note, CIT is concurrently produced with NO by eNOS, and recycled to de novo ARG [63]. It is possible that CIT supplementation stimulated the production of NO and CIT, but the effect on FMD was not evident in the absence of endothelial dysfunction. Nonetheless, the increase in the ARG/ADMA ratio by CIT may have vascular benefits, since an increase in this ratio by 1 SD may decrease CVD risk by 20% [64].
Oxidative stress markers were not improved by both supplementations. In healthy adults, 200–1000 mg of GSH daily for 4 weeks did not improve microvascular endothelial function and malondialdehyde levels [65,66]. Recently, whole blood GSH was elevated after 1 month with 250 or 1000 mg of GSH supplementation [67]. Despite no improvement in the oxidative stress markers, CIT+GSH increased FMD by improving eNOS function via increased ARG availability [33]. The ability of CIT+GSH to increase NO production was demonstrated in human umbilical vein endothelial cells after exposure for 24 h to the combination but not to CIT and GSH alone [34]. Thus, GSH provides an augmenting effect to the conversion of ARG to NO [34].
There are some limitations in the present study. The sample size was relatively small and included healthy postmenopausal women. FBG was not considered for randomization, which resulted to be higher in the CIT+GSH group. Future studies might investigate the effects of CIT and CIT+GSH in individuals with prediabetes. A GSH dose greater than 200 mg daily for longer than 4 weeks of supplementation may reduce markers of oxidative stress, as previously shown [67]. We measured serum levels of superoxide dismutase and glutathione peroxidase, two intracellular enzymes, rather than intracellular enzymatic activity. A statistical limitation could be a “regression to the mean” phenomenon when examining changes in FMD from baseline. However, there were no significant decreases in FMD in the placebo group after the 4-week intervention, which supports our conclusion of CIT+GSH being a viable route to improve endothelial function in healthy postmenopausal women.

5. Conclusions

Four weeks of CIT+GSH supplementation improves brachial artery FMD in apparently healthy postmenopausal women with slightly elevated FBG. CIT+GSH reduced brachial PWV and attenuates BP responses to sympathetic activation. These beneficial effects on the endothelial function and BP reactivity may be attributed to an increased ARG/ADMA ratio. Therefore, CIT+GSH supplementation may reduce the risk of cardiovascular events during physiological stress in postmenopausal women. Although CIT supplementation alone caused greater increases in the serum ARG levels and ARG/ADMA ratio, it did not improve FMD or BP responses to CPT in healthy postmenopausal women.

Author Contributions

A.F., M.M. and D.N. were responsible for the study design. A.F. was responsible for the conduction of the study. A.M., S.M.F., M.A.M., Y.K. and K.N.D. performed the experiment and data collection. A.F., A.M., S.M.F., M.A.M., Y.K. and K.N.D. participated in the data analysis and interpretation. A.F., M.A.M., Y.K. and K.N.D. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by Kirin Holdings Co., Ltd., grant A20-0164-001.

Institutional Review Board Statement

The experimental protocol and informed consent was approved by Texas Tech University Institutional Review Board.

Informed Consent Statement

Written informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available upon request from the corresponding author.

Acknowledgments

The authors recognize the cooperation and enthusiasm of our participants.

Conflicts of Interest

M.M. and D.N. are employees of Kirin Holdings Co., Ltd. M.M., D.N. and Kirin had no influence on participant handling, data collection, analysis or interpretation, and manuscript writing. The other authors declare no conflict of interest.

Abbreviations

ADMAAsymmetric dimethylarginine
ARGL-Arginine
baPWVBrachial-ankle pulse wave velocity
BPBlood pressure
cdPWVCarotid-distal pulse wave velocity
cfPWVCarotid-femoral pulse wave velocity
CITL-citrulline
CPTCold pressor test
crPWVCarotid-radial pulse wave velocity
CVDCardiovascular disease
DBPDiastolic blood pressure
eNOSEndothelial nitric oxide synthase
faPWVFemoral-ankle pulse wave velocity
FBGFasting blood glucose
FMDFlow-mediated dilation
GSHGlutathione
MAPMean arterial pressure
NONitric oxide
NOxNO metabolites
ORNOrnithine
PWVPulse wave velocity
SBPSystolic blood pressure
SDStandard deviation
SEStandard error

References

  1. Rossi, G.P.; Seccia, T.M.; Nussdorfer, G.G. Reciprocal regulation of endothelin-1 and nitric oxide: Relevance in the physiology and pathology of the cardiovascular system. Int. Rev. Cytol. 2001, 209, 241–272. [Google Scholar]
  2. Förstermann, U.; Sessa, W.C. Nitric oxide synthases: Regulation and function. Eur. Heart J. 2011, 33, 829–837. [Google Scholar] [CrossRef] [Green Version]
  3. Deanfield, J.E.; Halcox, J.P.; Rabelink, T.J. Endothelial function and dysfunction: Testing and clinical relevance. Circulation 2007, 115, 1285–1295. [Google Scholar] [CrossRef]
  4. Klawitter, J.; Hildreth, K.L.; Christians, U.; Kohrt, W.M.; Moreau, K.L. A relative L-arginine deficiency contributes to endothelial dysfunction across the stages of the menopausal transition. Physiol. Rep. 2017, 5, e13409. [Google Scholar] [CrossRef]
  5. Pernow, J.; Jung, C. Arginase as a potential target in the treatment of cardiovascular disease: Reversal of arginine steal? Cardiovasc. Res. 2013, 98, 334–343. [Google Scholar] [CrossRef] [Green Version]
  6. Berkowitz, D.E.; White, R.; Li, D.C.; Minhas, K.M.; Cernetich, A.; Kim, S.; Burke, S.; Shoukas, A.A.; Nyhan, D.; Champion, H.C.; et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003, 108, 2000–2006. [Google Scholar] [CrossRef] [Green Version]
  7. Bode-Boger, S.M.; Scalera, F.; Ignarro, L.J. The l-arginine paradox: Importance of the l-arginine/asymmetrical dimethylarginine ratio. Pharmacol. Ther. 2007, 114, 295–306. [Google Scholar] [CrossRef] [PubMed]
  8. Boger, R.H.; Bode-Boger, S.M.; Szuba, A.; Tsao, P.S.; Chan, J.R.; Tangphao, O.; Blaschke, T.F.; Cooke, J.P. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998, 98, 1842–1847. [Google Scholar] [CrossRef] [Green Version]
  9. Sydow, K.; Schwedhelm, E.; Arakawa, N.; Bode-Boger, S.M.; Tsikas, D.; Hornig, B.; Frolich, J.C.; Boger, R.H. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: Effects of L-arginine and B vitamins. Cardiovasc. Res. 2003, 57, 244–252. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Moreau, K.L.; Deane, K.D.; Meditz, A.L.; Kohrt, W.M. Tumor necrosis factor-alpha inhibition improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. Atherosclerosis 2013, 230, 390–396. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Moreau, K.L.; Hildreth, K.L.; Meditz, A.L.; Deane, K.D.; Kohrt, W.M. Endothelial function is impaired across the stages of the menopause transition in healthy women. J. Clin. Endocrinol. Metab. 2012, 97, 4692–4700. [Google Scholar] [CrossRef] [Green Version]
  12. Tomiyama, H.; Ishizu, T.; Kohro, T.; Matsumoto, C.; Higashi, Y.; Takase, B.; Suzuki, T.; Ueda, S.; Yamazaki, T.; Furumoto, T.; et al. Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension. Int. J. Cardiol. 2018, 253, 161–166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Rossi, R.; Chiurlia, E.; Nuzzo, A.; Cioni, E.; Origliani, G.; Modena, M.G. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women. J. Am. Coll. Cardiol. 2004, 44, 1636–1640. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Wenner, M.M.; Greaney, J.L.; Matthews, E.L.; McGinty, S.; Kaur, J.; Vongpatanasin, W.; Fadel, P.J. Influence of Age and Estradiol on Sympathetic Nerve Activity Responses to Exercise in Women. Med. Sci. Sports Exerc. 2022, 54, 408–416. [Google Scholar] [CrossRef]
  15. Coutinho, T.; Borlaug, B.A.; Pellikka, P.A.; Turner, S.T.; Kullo, I.J. Sex differences in arterial stiffness and ventricular-arterial interactions. J. Am. Coll. Cardiol. 2013, 61, 96–103. [Google Scholar] [CrossRef] [Green Version]
  16. Keller-Ross, M.L.; Cunningham, H.A.; Carter, J.R. Impact of age and sex on neural cardiovascular responsiveness to cold pressor test in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2020, 319, R288–R295. [Google Scholar] [CrossRef]
  17. Baker, S.E.; Limberg, J.K.; Ranadive, S.M.; Joyner, M.J. Neurovascular control of blood pressure is influenced by aging, sex, and sex hormones. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2016, 311, R1271–R1275. [Google Scholar] [CrossRef]
  18. Menkes, M.S.; Matthews, K.A.; Krantz, D.S.; Lundberg, U.; Mead, L.A.; Qaqish, B.; Liang, K.Y.; Thomas, C.B.; Pearson, T.A. Cardiovascular reactivity to the cold pressor test as a predictor of hypertension. Hypertension 1989, 14, 524–530. [Google Scholar] [CrossRef] [Green Version]
  19. Han, Y.; Du, J.; Wang, J.; Liu, B.; Yan, Y.L.; Deng, S.B.; Zou, Y.; Jing, X.D.; Du, J.L.; Liu, Y.J.; et al. Cold Pressor Test in Primary Hypertension: A Cross-Sectional Study. Front. Cardiovasc. Med. 2022, 9, 860322. [Google Scholar] [CrossRef]
  20. Parker, B.A.; Smithmyer, S.L.; Jarvis, S.S.; Ridout, S.J.; Pawelczyk, J.A.; Proctor, D.N. Evidence for reduced sympatholysis in leg resistance vasculature of healthy older women. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, H1148–H1156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Bode-Boger, S.M.; Muke, J.; Surdacki, A.; Brabant, G.; Boger, R.H.; Frolich, J.C. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc. Med. 2003, 8, 77–81. [Google Scholar] [CrossRef] [Green Version]
  22. Huang, J.; Ladeiras, D.; Yu, Y.; Ming, X.F.; Yang, Z. Detrimental Effects of Chronic L-Arginine Rich Food on Aging Kidney. Front. Pharmacol. 2020, 11, 582155. [Google Scholar] [CrossRef]
  23. Shatanawi, A.; Momani, M.S.; Al-Aqtash, R.; Hamdan, M.H.; Gharaibeh, M.N. L-Citrulline Supplementation Increases Plasma Nitric Oxide Levels and Reduces Arginase Activity in Patients with Type 2 Diabetes. Front. Pharmacol. 2020, 11, 584669. [Google Scholar] [PubMed]
  24. Schwedhelm, E.; Maas, R.; Freese, R.; Jung, D.; Lukacs, Z.; Jambrecina, A.; Spickler, W.; Schulze, F.; Boger, R.H. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: Impact on nitric oxide metabolism. Br. J. Clin. Pharmacol. 2008, 65, 51–59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Bailey, S.J.; Blackwell, J.R.; Lord, T.; Vanhatalo, A.; Winyard, P.G.; Jones, A.M. L-citrulline supplementation improves O2 uptake kinetics and high-intensity exercise performance in humans. J. Appl. Physiol. 2015, 119, 385–395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Morita, M.; Hayashi, T.; Ochiai, M.; Maeda, M.; Yamaguchi, T.; Ina, K.; Kuzuya, M. Oral supplementation with a combination of l-citrulline and l-arginine rapidly increases plasma l-arginine concentration and enhances NO bioavailability. Biochem. Biophys. Res. Commun. 2014, 454, 53–57. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Ochiai, M.; Hayashi, T.; Morita, M.; Ina, K.; Maeda, M.; Watanabe, F.; Morishita, K. Short-term effects of l-citrulline supplementation on arterial stiffness in middle-aged men. Int. J. Cardiol. 2012, 155, 257–261. [Google Scholar]
  28. Wong, A.; Alvarez-Alvarado, S.; Jaime, S.J.; Kinsey, A.W.; Spicer, M.T.; Madzima, T.A.; Figueroa, A. Combined whole body vibration training and L-citrulline supplementation improves pressure wave reflection in obese postmenopausal women. Appl. Physiol. Nutr. Metabol. 2016, 41, 292–297. [Google Scholar] [CrossRef] [PubMed]
  29. Figueroa, A.; Alvarez-Alvarado, S.; Ormsbee, M.J.; Madzima, T.A.; Campbell, J.C.; Wong, A. Impact of L-citrulline supplementation and whole-body vibration training on arterial stiffness and leg muscle function in obese postmenopausal women with high blood pressure. Exp. Gerontol. 2015, 63, 35–40. [Google Scholar] [CrossRef]
  30. Figueroa, A.; Alvarez-Alvarado, S.; Jaime, S.J.; Kalfon, R. l-Citrulline supplementation attenuates blood pressure, wave reflection and arterial stiffness responses to metaboreflex and cold stress in overweight men. Br. J. Nutr. 2016, 116, 279–285. [Google Scholar] [CrossRef] [Green Version]
  31. Figueroa, A.; Trivino, J.A.; Sanchez-Gonzalez, M.A.; Vicil, F. Oral L-citrulline supplementation attenuates blood pressure response to cold pressor test in young men. Am. J. Hypertens. 2010, 23, 12–16. [Google Scholar] [CrossRef] [Green Version]
  32. Jaime, S.J.; Nagel, J.; Maharaj, A.; Fischer, S.M.; Schwab, E.; Martinson, C.; Radtke, K.; Mikat, R.P.; Figueroa, A. L-Citrulline supplementation attenuates aortic pulse pressure and wave reflection responses to cold stress in older adults. Exp. Gerontol. 2022, 159, 111685. [Google Scholar] [CrossRef] [PubMed]
  33. Matsuo, K.; Yabuki, Y.; Fukunaga, K. Combined l-citrulline and glutathione administration prevents neuronal cell death following transient brain ischemia. Brain Res. 2017, 1663, 123–131. [Google Scholar] [CrossRef] [PubMed]
  34. McKinley-Barnard, S.; Andre, T.; Morita, M.; Willoughby, D.S. Combined L-citrulline and glutathione supplementation increases the concentration of markers indicative of nitric oxide synthesis. J. Int. Soc. Sport. Nutr. 2015, 12, 27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Klatsky, A.L. Alcohol and cardiovascular diseases: Where do we stand today? J. Intern. Med. 2015, 278, 238–250. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Kwon, C.H.; Kim, W.; Shin, J.H.; Lee, C.J.; Kim, H.C.; Kang, S.H.; Jung, M.H.; Kim, D.H.; Lee, J.H.; Kim, H.L.; et al. Office Blood Pressure Range and Cardiovascular Events in Patients With Hypertension: A Nationwide Cohort Study in South Korea. J. Am. Heart Assoc. 2021, 10, e017890. [Google Scholar] [CrossRef]
  37. Envelope, S. Create a Blocked Randomisation List. Obtenido de Sealed Envelope. 2019. Available online: https://www.sealedenvelope.com/simple-randomiser/v1/lists (accessed on 20 June 2020).
  38. Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur. Heart J. 2010, 31, 2338–2350. [Google Scholar] [CrossRef]
  39. Ras, R.T.; Streppel, M.T.; Draijer, R.; Zock, P.L. Flow-mediated dilation and cardiovascular risk prediction: A systematic review with meta-analysis. Int. J. Cardiol. 2013, 168, 344–351. [Google Scholar] [CrossRef] [PubMed]
  40. Morita, M.; Sakurada, M.; Watanabe, F.; Yamasaki, T.; Ezaki, H.; Morishita, K.; Miyake, T. Effects of oral L-citrulline supplementation on lipoprotein oxidation and endothelial dysfunction in humans with vasospastic angina. Immunol. Endocrin. Metab. Agent. Med. Chem. 2013, 13, 214–220. [Google Scholar] [CrossRef] [Green Version]
  41. Bai, Y.; Sun, L.; Yang, T.; Sun, K.; Chen, J.; Hui, R. Increase in fasting vascular endothelial function after short-term oral L-arginine is effective when baseline flow-mediated dilation is low: A meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2009, 89, 77–84. [Google Scholar] [CrossRef] [Green Version]
  42. Matsuzawa, Y.; Kwon, T.G.; Lennon, R.J.; Lerman, L.O.; Lerman, A. Prognostic Value of Flow-Mediated Vasodilation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A Systematic Review and Meta-Analysis. J. Am. Heart Assoc. 2015, 4, e002270. [Google Scholar] [CrossRef] [Green Version]
  43. Heiss, C.; Rodriguez-Mateos, A.; Bapir, M.; Skene, S.S.; Sies, H.; Kelm, M. Flow-mediated dilation reference values for evaluation of endothelial function and cardiovascular health. Cardiovasc. Res. 2022, 119, 283–293. [Google Scholar] [CrossRef]
  44. Yeboah, J.; Crouse, J.R.; Hsu, F.-C.; Burke, G.L.; Herrington, D.M. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: The Cardiovascular Health Study. Circulation 2007, 115, 2390–2397. [Google Scholar] [CrossRef] [PubMed]
  45. Tirosh, A.; Shai, I.; Tekes-Manova, D.; Israeli, E.; Pereg, D.; Shochat, T.; Kochba, I.; Rudich, A.; Israeli Diabetes Research, G. Normal fasting plasma glucose levels and type 2 diabetes in young men. N. Engl. J. Med. 2005, 353, 1454–1462. [Google Scholar] [CrossRef] [PubMed]
  46. Su, Y.; Liu, X.M.; Sun, Y.M.; Jin, H.B.; Fu, R.; Wang, Y.Y.; Wu, Y.; Luan, Y. The relationship between endothelial dysfunction and oxidative stress in diabetes and prediabetes. Int. J. Clin. Pract. 2008, 62, 877–882. [Google Scholar] [CrossRef]
  47. DeVan, A.E.; Eskurza, I.; Pierce, G.L.; Walker, A.E.; Jablonski, K.L.; Kaplon, R.E.; Seals, D.R. Regular aerobic exercise protects against impaired fasting plasma glucose-associated vascular endothelial dysfunction with aging. Clin. Sci. 2013, 124, 325–331. [Google Scholar] [CrossRef] [Green Version]
  48. McEniery, C.M.; Yasmin; Hall, I.R.; Qasem, A.; Wilkinson, I.B.; Cockcroft, J.R. Normal vascular aging: Differential effects on wave reflection and aortic pulse wave velocity: The Anglo-Cardiff Collaborative Trial (ACCT). J. Am. Coll. Cardiol. 2005, 46, 1753–1760. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Yamashina, A.; Tomiyama, H.; Takeda, K.; Tsuda, H.; Arai, T.; Hirose, K.; Koji, Y.; Hori, S.; Yamamoto, Y. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens. Res. 2002, 25, 359–364. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Naka, K.K.; Tweddel, A.C.; Doshi, S.N.; Goodfellow, J.; Henderson, A.H. Flow-mediated changes in pulse wave velocity: A new clinical measure of endothelial function. Eur. Heart J. 2006, 27, 302–309. [Google Scholar] [CrossRef] [Green Version]
  51. Kamran, H.; Salciccioli, L.; Ko, E.H.; Qureshi, G.; Kazmi, H.; Kassotis, J.; Lazar, J. Effect of reactive hyperemia on carotid-radial pulse wave velocity in hypertensive participants and direct comparison with flow-mediated dilation: A pilot study. Angiology 2010, 61, 100–106. [Google Scholar] [CrossRef]
  52. Kobayashi, Y.; Narita, K.; Chiba, K.; Takemoto, H.; Morita, M.; Morishita, K. Effects of L-citrulline diet on stress-induced cold hypersensitivity in mice. Pharmacogn. Res. 2014, 6, 297–302. [Google Scholar] [CrossRef] [Green Version]
  53. Choi, H.M.; Stebbins, C.L.; Nho, H.; Kim, K.A.; Kim, C.; Kim, J.K. Skeletal muscle metaboreflex is enhanced in postmenopausal women. Eur. J. Appl. Physiol. 2012, 112, 2671–2678. [Google Scholar] [CrossRef] [PubMed]
  54. Luiking, Y.C.; Ten Have, G.A.; Wolfe, R.R.; Deutz, N.E. Arginine de novo and nitric oxide production in disease states. Am. J. Physiol. Endocrinol. Metab. 2012, 303, E1177–E1189. [Google Scholar] [CrossRef] [Green Version]
  55. Celik, M.; Unal, H.U. The l-Arginine/Asymmetric Dimethylarginine (ADMA) Ratio in Health and Disease: An Overview. In L-Arginine in Clinical Nutrition; Patel, V.B., Preedy, V.R., Rajendram, R., Eds.; Springer International Publishing: Cham, Switzerland, 2017; pp. 225–238. [Google Scholar]
  56. Luneburg, N.; Xanthakis, V.; Schwedhelm, E.; Sullivan, L.M.; Maas, R.; Anderssohn, M.; Riederer, U.; Glazer, N.L.; Vasan, R.S.; Boger, R.H. Reference intervals for plasma L-arginine and the L-arginine:asymmetric dimethylarginine ratio in the Framingham Offspring Cohort. J. Nutr. 2011, 141, 2186–2190. [Google Scholar] [CrossRef] [Green Version]
  57. Ellger, B.; Richir, M.C.; van Leeuwen, P.A.; Debaveye, Y.; Langouche, L.; Vanhorebeek, I.; Teerlink, T.; Van den Berghe, G. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity. Endocrinology 2008, 149, 3148–3157. [Google Scholar] [CrossRef] [Green Version]
  58. Bogle, R.G.; MacAllister, R.J.; Whitley, G.S.; Vallance, P. Induction of NG-monomethyl-L-arginine uptake: A mechanism for differential inhibition of NO synthases? Am. J. Physiol. 1995, 269, C750–C756. [Google Scholar] [CrossRef] [PubMed]
  59. Palloshi, A.; Fragasso, G.; Piatti, P.; Monti, L.D.; Setola, E.; Valsecchi, G.; Galluccio, E.; Chierchia, S.L.; Margonato, A. Effect of oral L-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise tests, and normal coronary arteries. Am. J. Cardiol. 2004, 93, 933–935. [Google Scholar] [CrossRef] [PubMed]
  60. Monti, L.D.; Casiraghi, M.C.; Setola, E.; Galluccio, E.; Pagani, M.A.; Quaglia, L.; Bosi, E.; Piatti, P. L-arginine enriched biscuits improve endothelial function and glucose metabolism: A pilot study in healthy subjects and a cross-over study in subjects with impaired glucose tolerance and metabolic syndrome. Metabolism 2013, 62, 255–264. [Google Scholar] [CrossRef]
  61. Blum, A.; Hathaway, L.; Mincemoyer, R.; Schenke, W.H.; Kirby, M.; Csako, G.; Waclawiw, M.A.; Panza, J.A.; Cannon, R.O., III. Effects of oral L-arginine on endothelium-dependent vasodilation and markers of inflammation in healthy postmenopausal women. J. Am. Coll. Cardiol. 2000, 35, 271–276. [Google Scholar] [CrossRef] [Green Version]
  62. Esen, O.; Eser, M.C.; Abdioglu, M.; Benesova, D.; Gabrys, T.; Karayigit, R. Eight Days of L-Citrulline or L-Arginine Supplementation Did Not Improve 200-m and 100-m Swimming Time Trials. Int. J. Environ. Res. Public Health 2022, 19, 4462. [Google Scholar] [CrossRef]
  63. Flam, B.R.; Eichler, D.C.; Solomonson, L.P. Endothelial nitric oxide production is tightly coupled to the citrulline-NO cycle. Nitric Oxide 2007, 17, 115–121. [Google Scholar] [CrossRef]
  64. Yu, E.; Ruiz-Canela, M.; Hu, F.B.; Clish, C.B.; Corella, D.; Salas-Salvado, J.; Hruby, A.; Fito, M.; Liang, L.; Toledo, E.; et al. Plasma Arginine/Asymmetric Dimethylarginine Ratio and Incidence of Cardiovascular Events: A Case-Cohort Study. J. Clin. Endocrinol. Metab. 2017, 102, 1879–1888. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Campolo, J.; Bernardi, S.; Cozzi, L.; Rocchiccioli, S.; Dellanoce, C.; Cecchettini, A.; Tonini, A.; Parolini, M.; De Chiara, B.; Micheloni, G.; et al. Medium-term effect of sublingual l-glutathione supplementation on flow-mediated dilation in subjects with cardiovascular risk factors. Nutrition 2017, 38, 41–47. [Google Scholar] [CrossRef] [PubMed]
  66. Allen, J.; Bradley, R.D. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J. Altern. Complement. Med. 2011, 17, 827–833. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Richie, J.P., Jr.; Nichenametla, S.; Neidig, W.; Calcagnotto, A.; Haley, J.S.; Schell, T.D.; Muscat, J.E. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur. J. Nutr. 2015, 54, 251–263. [Google Scholar] [CrossRef]
Nutrients 15 01557 g001 550
Figure 1. CONSORT flow chart of participants through the study. CIT, citrulline, CIT+GSH, and CIT+glutathione.
Figure 1. CONSORT flow chart of participants through the study. CIT, citrulline, CIT+GSH, and CIT+glutathione.
Nutrients 15 01557 g001
Nutrients 15 01557 g002 550
Figure 2. Changes (Δ) in brachial artery flow-mediated dilation (ΔFMD%) from 0 to 4 weeks. Abbreviations: CIT, citrulline; CIT+GSH, CIT+glutathione. * p < 0.05 vs. placebo.
Figure 2. Changes (Δ) in brachial artery flow-mediated dilation (ΔFMD%) from 0 to 4 weeks. Abbreviations: CIT, citrulline; CIT+GSH, CIT+glutathione. * p < 0.05 vs. placebo.
Nutrients 15 01557 g002
Nutrients 15 01557 g003 550
Figure 3. Relationship between changes (Δ) in the brachial artery flow-mediated dilation (ΔFMD%) from 0 to 4 weeks and baseline (0 week) FMD%. Abbreviations: CIT, citrulline; CIT+GSH, CIT+glutathione.
Figure 3. Relationship between changes (Δ) in the brachial artery flow-mediated dilation (ΔFMD%) from 0 to 4 weeks and baseline (0 week) FMD%. Abbreviations: CIT, citrulline; CIT+GSH, CIT+glutathione.
Nutrients 15 01557 g003
Nutrients 15 01557 g004 550
Figure 4. Changes (Δ) in (A) the brachial systolic blood pressure SBP (SBP), (B) brachial mean arterial pressure (MAP), (C) aortic SBP, and (D) aortic MAP to the cold pressor test before and after supplementations. Abbreviations: CIT, citrulline; CIT+GSH, CIT+glutathione. * p < 0.05 before vs. after, † p < 0.05 vs. placebo and CIT, ‡ p < 0.05 vs. placebo.
Figure 4. Changes (Δ) in (A) the brachial systolic blood pressure SBP (SBP), (B) brachial mean arterial pressure (MAP), (C) aortic SBP, and (D) aortic MAP to the cold pressor test before and after supplementations. Abbreviations: CIT, citrulline; CIT+GSH, CIT+glutathione. * p < 0.05 before vs. after, † p < 0.05 vs. placebo and CIT, ‡ p < 0.05 vs. placebo.
Nutrients 15 01557 g004
Nutrients 15 01557 g005 550
Figure 5. Changes (Δ) in serum levels of arginine (A), ornithine (B), and the arginine/ADMA ratio (C) from 0–4 weeks in the three groups. Values are the mean ± SE. Abbreviations: ARG, arginine; ADMA, asymmetric dimethylarginine; CIT, citrulline; CIT+GSH, CIT+glutathione. * p < 0.05 vs. placebo and CIT+GSH; † p < 0.05 vs. CIT+GSH.
Figure 5. Changes (Δ) in serum levels of arginine (A), ornithine (B), and the arginine/ADMA ratio (C) from 0–4 weeks in the three groups. Values are the mean ± SE. Abbreviations: ARG, arginine; ADMA, asymmetric dimethylarginine; CIT, citrulline; CIT+GSH, CIT+glutathione. * p < 0.05 vs. placebo and CIT+GSH; † p < 0.05 vs. CIT+GSH.
Nutrients 15 01557 g005
Table
Table 1. Participant characteristics and treatments.
Table 1. Participant characteristics and treatments.
Measures and MedicationPlacebo (n = 13)CIT (n = 13)CIT+GSH (n = 13)p
Age (years)60 ± 558 ± 458 ± 60.60
Height (m)1.58 ± 0.061.59 ± 0.081.59 ± 0.100.92
Body weight (kg)73.3 ± 9.372.1 ± 11.275.5 ± 15.70.94
BMI (kg/m2)29.3 ± 3.429.0 ± 4.829.5 ± 4.20.91
WC (cm)93.3 ± 8.593.1 ± 12.691.5 ± 11.00.65
Total fat mass (%)45 ± 542 ± 746 ± 50.18
Total lean mass (%)54 ± 555 ± 556 ± 60.18
FBG (mg/dL)87 ± 790 ± 694 ± 7 †0.04
Medication (n)
ARB/ACE inhibitors213
Diuretics102
Ca2+ channel blockers100
Values are the mean ± SD or number (n) of participants. Abbreviations: BMI, body mass index; WC, waist circumference; FBG, fasting blood glucose; CIT, citrulline; GSH, glutathione; ARB, angiotensin receptor blocker; ACE, angiotensin converting enzyme; † vs. placebo.
Table
Table 2. Brachial artery endothelial function and arterial stiffness.
Table 2. Brachial artery endothelial function and arterial stiffness.
MeasurePlaceboCITCIT+GSH
BeforeAfterBeforeAfterBeforeAfterp
FMD (%)4.8 ± 2.24.8 ± 2.95.0 ± 2.05.7 ± 3.53.1 ± 1.86.0 ± 3.0 *‡0.04
cfPWV (m/s)7.6 ± 1.47.6 ± 1.16.9 ± 0.87.3 ± 0.87.3 ± 0.77.3 ± 1.30.28
crPWV (m/s) 8.3 ± 1.7 8.3 ± 1.2 8.5 ± 1.2 8.5 ± 1.8 8.5 ± 0.9 7.9 ± 0.9 * 0.51
cdPWV (m/s) 8.9 ± 1.5 8.2 ± 1.1 8.8 ± 0.8 8.4 ± 0.9 8.2 ± 0.9 8.2 ± 1.1 0.23
faPWV (m/s) 8.5 ± 0.3 8.7 ± 0.3 9.0 ± 0.3 9.3 ± 0.3 9.0 ± 0.3 8.8 ± 0.3 0.69
Values are the mean ± SD. Abbreviations: cfPWV, carotid-femoral PWV; crPWV, carotid-radial PWV; cdPWV, carotid-distal PWV; CIT, citrulline; CIT+GSH, CIT+glutathione; faPWV, femoral-ankle PWV. p-values are the time-by-group interaction from two-way repeated measures ANOVA. * p < 0.05 vs. before; ‡ p < 0.05 vs. placebo.
Table
Table 3. Brachial and aortic blood pressures at rest and during CPT.
Table 3. Brachial and aortic blood pressures at rest and during CPT.
MeasureConditionPlaceboCITCIT+GSH
BeforeAfterBeforeAfterBeforeAfterp
Brachial SBP (mmHg)Rest113 ± 13 111 ± 12 113 ± 13 114 ± 11 110 ± 12 115 ± 12 0.27
CPT135 ± 15136 ± 12127 ± 13132 ± 14141 ± 18135 ± 16
Brachial DBP (mmHg)Rest75 ± 875 ± 871 ± 971 ± 971 ± 1173 ± 80.69
CPT91 ± 1193 ± 881 ± 983 ± 888 ± 1489 ± 10
Brachial MAP (mmHg)Rest88 ± 987 ± 985 ± 1085 ± 784 ± 1187 ± 70.40
CPT105 ± 11107 ± 996 ± 999 ± 9106 ± 14103 ± 11
Aortic SBP (mmHg)Rest107 ± 13105 ± 11108 ± 13109 ± 10104 ± 11107 ± 90.35
CPT129 ± 15129 ± 12121 ± 14125 ± 13133 ± 18128 ± 16
Aortic DBP (mmHg)Rest76 ± 876 ± 872 ± 972 ± 972 ± 1174 ± 80.66
CPT92 ± 1194 ± 882 ± 983 ± 890 ± 1490 ± 10
Aortic MAP (mmHg)Rest87 ± 986 ± 984 ± 1084 ± 883 ± 1185 ± 70.70
CPT104 ± 11106 ± 995 ± 1097 ± 9104 ± 14102 ± 11
AIx75 (%)Rest27 ± 628 ± 730 ± 829 ± 827 ± 527 ± 60.88
CPT33 ± 631 ± 732 ± 832 ± 633 ± 830 ± 7
Tr (ms)Rest137 ± 6138 ± 7135 ± 8135 ± 8138 ± 9136 ± 70.29
CPT135 ± 8139 ± 11135 ± 8136 ± 10138 ± 8139 ± 8
Values are the mean ± SD. Abbreviations: AIx, augmentation index normalized to the heart rate of 75; CIT, citrulline; CIT+GSH, CIT+glutathione; DBP, diastolic blood pressure; MAP, mean arterial pressure; SBP, systolic blood pressure; Tr, reflection time. p-values of ANOVA time-by-group interaction.
Table
Table 4. Serum markers of arginine metabolism, glucose control, and oxidative stress.
Table 4. Serum markers of arginine metabolism, glucose control, and oxidative stress.
MeasurePlaceboCITCIT+GSH
BeforeAfterBeforeAfterBeforeAfterp
Arginine (µM/L) 127 ± 21 135 ± 32 121 ± 21 168 ± 36 *† 117 ± 25 128 ± 19 0.005
Citrulline (µM/L) 41 ± 10 41 ± 13 40 ± 8 49 ± 13 * 38 ± 10 39 ± 7 0.09
Ornithine (µM/L) 106 ± 28 120 ± 34 110 ± 20 149 ± 38 ‡# 104 ± 25 114 ± 24 0.043
ADMA (mM/L) 0.54 ± 0.05 0.55 ± 0.05 0.54 ± 0.06 0.56 ± 0.06 * 0.55 ± 0.07 0.54 ± 0.08 0.27
Arginine/ADMA 240 ± 50 248 ± 61 228 ± 50 299 ± 48 *† 215 ± 47 237 ± 37 * 0.007
Arginase-I (ng/mL) 87 ± 2 87 ± 2 88 ± 3 87 ± 3 ‡ 90 ± 3 89 ± 3 0.32
Glucose (mg/dL) 87 ± 7 87 ± 7 90 ± 6 91 ± 10 94 ± 7 94 ± 8 0.89
Insulin (mIU/mL) 15 ± 4 14 ± 4 15 ± 6 15 ± 5 12 ± 4 12 ± 5 0.75
HOMA-IR 3.1 ± 1.0 3.1 ± 1.1 3.4 ± 1.5 3.4 ± 1.3 2.7 ± 1.1 2.9 ± 1.1 0.82
GPx (µmol/L) 393 ± 44 399 ± 44 396 ± 43 400 ± 43 435 ± 35 439 ± 33 * 0.75
SOD (ng/mL) 20 ± 3 20 ± 2 21 ± 3 20 ± 2 21 ± 4 20 ± 3 0.42
Ox-LDL (U/L) 65 ± 13 65 ± 14 69 ± 12 68 ± 12 72 ± 12 72 ± 12 0.53
MDA (µm/L) 1.0 ± 0.37 1.1 ± 0.39 0.94 ± 0.39 0.99 ± 0.38 1.1 ± 0.45 1.0 ± 0.38 0.76
Data are the mean ± SD. p-values of ANOVA time-by-group interaction. Abbreviations: ADMA, asymmetric dimethylarginine; HOMA-IR, homeostatic model assessment for insulin resistance; GPx, glutathione peroxidase; SOD, superoxide dismutase; Ox-LDL, oxidized LDL; MDA, malondialdehyde. * p < 0.05 vs. before; ‡ p < 0.01 vs. before; † p < 0.05 vs. placebo and CIT+GSH; # p < 0.05 vs. CIT+GSH.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Figueroa, A.; Maharaj, A.; Kang, Y.; Dillon, K.N.; Martinez, M.A.; Morita, M.; Nogimura, D.; Fischer, S.M. Combined Citrulline and Glutathione Supplementation Improves Endothelial Function and Blood Pressure Reactivity in Postmenopausal Women. Nutrients 2023, 15, 1557. https://doi.org/10.3390/nu15071557

AMA Style

Figueroa A, Maharaj A, Kang Y, Dillon KN, Martinez MA, Morita M, Nogimura D, Fischer SM. Combined Citrulline and Glutathione Supplementation Improves Endothelial Function and Blood Pressure Reactivity in Postmenopausal Women. Nutrients. 2023; 15(7):1557. https://doi.org/10.3390/nu15071557

Chicago/Turabian Style

Figueroa, Arturo, Arun Maharaj, Yejin Kang, Katherine N. Dillon, Mauricio A. Martinez, Masahiko Morita, Dai Nogimura, and Stephen M. Fischer. 2023. "Combined Citrulline and Glutathione Supplementation Improves Endothelial Function and Blood Pressure Reactivity in Postmenopausal Women" Nutrients 15, no. 7: 1557. https://doi.org/10.3390/nu15071557

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop